SCHEMBL25185758

SCHEMBL25185758

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](Cc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.42
▸ PPARA Q07869 3/20 0.42
▸ ITGB1 P05556 2/20 0.40
▸ ITGA4 P13612 2/20 0.40
▸ ITGB7 P26010 1/20 0.40
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ NOS2 P35228 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ CTRB1 P17538 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ CETP P11597 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ SLC6A9 P48067 1/20 0.37
▸ TBXA2R P21731 1/20 0.37
▸ PTGDR Q13258 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25186567 0.90 FFAR1 (0.39) PPARGPPARACTRB1MEN1KMT2A
SCHEMBL4600067 0.89 CTRB1 (0.40) PPARGPPARAITGB1ITGA4CTRB1
SCHEMBL4600752 0.89 CTRB1 (0.40) PPARGPPARAITGB1ITGA4CTRB1
SCHEMBL5407004 0.89 CTRB1 (0.40) PPARGPPARAITGB1ITGA4CTRB1
SCHEMBL30510366 0.89 CTRB1 (0.40) PPARGPPARAITGB1ITGA4CTRB1
SCHEMBL25182990 0.89 MEN1 (0.50) PPARGPPARAMEN1KMT2AATM
SCHEMBL25185914 0.88 ITGB1 (0.39) PPARGPPARAITGB1ITGA4ITGB7
SCHEMBL5403825 0.87 ITGA4 (0.42) PPARGPPARAITGB1ITGA4ITGB7
SCHEMBL30767800 0.87 ATM (0.39) PPARGPPARAITGB1ITGA4ITGB7
SCHEMBL25177964 0.87 ATM (0.39) PPARGPPARAITGB1ITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS PPARG 4292/4885PPARA 3880/4885ITGB1 4791/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS PPARG 4292/4885PPARA 3880/4885ITGB1 4791/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS PPARG 3626/4885PPARA 3079/4885ITGB1 4797/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS PPARG 4292/4885PPARA 3880/4885ITGB1 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback